Anzeige
Mehr »
Montag, 06.10.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken beweist seine Stärke - und American Critical Minerals sitzt direkt darauf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14Z20 | ISIN: GB00BZ21RF93 | Ticker-Symbol: N/A
1-Jahres-Chart  (nicht börsennotiert)
STALLERGENES GREER PLC Chart 1 Jahr

Aktuelle News zur STALLERGENES GREER

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.09.Stallergenes Greer and Nuance Pharma Enter Exclusive Long-term Partnership for Actair Sublingual Immunotherapy Tablet for the Treatment of House Dust Mite Allergy in China311Stallergenes Greer, a global leader in allergy therapeutics, and Nuance Pharma, an innovation-focused biopharmaceutical company based in China, today announced they have entered into an exclusive...
► Artikel lesen
30.07.Stallergenes Greer Announces Palforzia Featured on "The Balancing Act" Airing on Lifetime TV370National TV Segment Highlights FDA-Approved Oral Immunotherapy Treatment for Peanut Allergy Segment premiered on Wednesday, July 30 and will be rebroadcast on Thursday, July 31, at 7:30 a.m....
► Artikel lesen
03.07.Stallergenes Greer: Transition of Promotional Activities for Allergen Immunotherapy Drug Actair in Japan296Stallergenes Greer, Shionogi Co., Ltd. ("Shionogi") and CEOLIA Pharma Co. Ltd ("CEOLIA") today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes Greer's...
► Artikel lesen
12.06.Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025255Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow...
► Artikel lesen
STALLERGENES GREER Aktie jetzt für 0€ handeln
14.04.Stallergenes Greer: Positive Adherence Impact of IPUMP Connected Assistant for Sublingual Liquid Allergen Immunotherapy Treatment361Stallergenes Greer, a global leader in allergy therapeutics, will present positive results from its SPEED survey at the upcoming CFA congress (Congrès Francophone d'Allergologie, the French congress...
► Artikel lesen
04.03.Stallergenes Greer Announces Appointment of Andreas Amrein as Chief Executive Officer422Stallergenes Greer, a global leader in allergy therapeutics, today announced that the Board of Directors has appointed Andreas Amrein as Chief Executive Officer, with effect from April 1, 2025. After...
► Artikel lesen
09.01.Stallergenes Greer: European Commission Approves the Extension of the Indication of Palforzia to the Treatment of Toddlers With Confirmed Peanut Allergy360Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® (defatted...
► Artikel lesen
06.01.Stallergenes Greer: Science Awards for Allergy 2025: Call for Applications355The Stallergenes Greer Foundation is pleased to announce the launch of the 2025 edition of its Science Awards for Allergy, an initiative dedicated to recognising outstanding contributions to allergy...
► Artikel lesen
02.12.24Stallergenes Greer: Positive CHMP Opinion for the Extension of Indication of Palforzia for the Treatment of Toddlers With Confirmed Peanut Allergy434Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
► Artikel lesen
9 Nachrichten in den letzten 12 Monaten